Blackrock, INC Schedule 13G passive stakes

BlackRock, Inc. has disclosed an 11.8% beneficial ownership stake in BlueLinx Holdings Inc., holding 926,837 shares of common stock.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in First United Corp's common stock as of December 31, 2025.

BlackRock, Inc. has reported an increased beneficial ownership of 6.1% in Annexon Inc.'s common stock as of December 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.9% beneficial ownership stake in Intuitive Machines, Inc.'s Class A Stock as of December 31, 2025.

BlackRock, Inc. has reported a 6.8% passive ownership stake in American Battery Technology Co, holding over 8.8 million shares of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.1% beneficial ownership stake in Amylyx Pharmaceuticals, Inc. as of December 31, 2025.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in Inseego Corp. common stock as of December 31, 2025.

BlackRock, Inc. has reported a significant beneficial ownership stake of 13.7% in Insperity Inc., holding over 5.1 million shares.

BlackRock, Inc. has filed a Schedule 13G, reporting a 5.3% beneficial ownership stake in INHIBRX BIOSCIENCES, INC. as of December 31, 2025.

BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting a beneficial ownership of 8.9% in Hewlett Packard Enterprise Co.

BlackRock, Inc. has reported a 5.9% beneficial ownership stake in Forge Global Holdings, Inc., holding 813,292 shares of common stock as of December 31, 2025.

BlackRock, Inc. has reported a 9.1% beneficial ownership stake in BioMarin Pharmaceutical Inc., holding 17,560,751 common shares as of December 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 6.4% beneficial ownership stake in ACRES Commercial Realty Corp common stock.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in Cimpress PLC, holding 1,261,757 common shares as of December 31, 2025.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in CB Financial Services Inc., holding 254,204 shares of common stock as of December 31, 2025.

BlackRock, Inc. has reported a 5.2% beneficial ownership stake in NioCorp Developments Ltd., holding over 6.18 million common shares.

BlackRock, Inc. has reported an increased beneficial ownership of 6.8% in Cass Information Systems Inc., holding 895,886 shares of common stock.

BlackRock, Inc. has reported a beneficial ownership of 8.6% of Clearwater Paper Corp's common stock as of December 31, 2025.

BlackRock, Inc. has reported a 5.1% beneficial ownership stake in Affirm Holdings Inc. Class A stock as of December 31, 2025.

BlackRock, Inc. has reported a beneficial ownership of 7.9% in Adaptive Biotechnologies Corp's common stock, totaling 11,992,448 shares.

BlackRock, Inc. has increased its beneficial ownership in Cogent Biosciences, Inc. to 6.5% of common stock, holding over 11.3 million shares.

BlackRock, Inc. has reported a 6.6% beneficial ownership stake in Bentley Systems Inc.'s Class B Stock as of December 31, 2025.

BlackRock, Inc. has reported a beneficial ownership of 6.5% in Gossamer Bio, Inc. common stock as of December 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, disclosing its beneficial ownership in Eledon Pharmaceuticals, Inc. has fallen to 4.6% of common stock.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a 9.8% beneficial ownership stake in StoneCo Ltd.'s Class A Stock.

BlackRock, Inc. has reported a 15.0% beneficial ownership stake in Arrowhead Pharmaceuticals Inc., holding over 20 million shares as of December 31, 2025.

BlackRock, Inc. has reported an increased beneficial ownership of 12.1% in Consolidated Water Co. Ltd., holding 1,921,141 common shares as of December 31, 2025.

BlackRock, Inc. has reported a 5.6% beneficial ownership stake in Arrivent Biopharma Inc., holding over 2.3 million common shares as of December 31, 2025.

BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 6.2% of Astera Labs Inc.'s common stock as of December 31, 2025.

BlackRock, Inc. has reported a 5.2% beneficial ownership stake in Compass Therapeutics, Inc. as of December 31, 2025, as disclosed in a Schedule 13G filing dated January 21, 2026.